Form 4: Janux Therapeutics Director Jay Lichter Sells Shares

Director Jay Lichter reports selling Janux Therapeutics (JANX) shares held directly and indirectly through affiliated investment partnerships.

Summary

• Jay Lichter, a director of Janux Therapeutics, reported the sale of common stock on June 3, 2024.
• The sales were executed at a weighted average price of $54.75 per share.
• Lichter sold 677,279 shares held indirectly through Avalon Ventures XI, L.P., reducing the indirect holdings to 3,271,216 shares.
• He also sold 131,196 shares held indirectly through Avalon BioVentures I, LP, decreasing the indirect holdings to 633,673 shares.
• Additionally, 691,525 shares held indirectly through Avalon BioVentures SPV I, L.P. were sold, leaving 3,340,018 shares held indirectly.
• Lichter directly holds 4,583 shares after these transactions.
• The reported transactions were made pursuant to pro rata distributions in kind.

Sentiment

Score: 5

Explanation: The document is a standard SEC Form 4 filing, reporting the sale of shares by a company director. It doesn't inherently convey positive or negative sentiment, but the market may interpret the sale as slightly negative depending on the context.

Industry Context

Sales by company insiders are a common occurrence and are closely watched by investors for signals about the company's prospects. It's important to consider the context of these sales, such as the size of the sale relative to the insider's holdings and any stated reasons for the transaction.

Stakeholder Impact

• Shareholders may react to the news of the director's share sale, potentially impacting the stock price.

Key Dates